Alnylam Pharmaceuticals, Inc. (ALNY) Posts Wider than Expected Q2 Loss
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $241.89 -1.47%
EPS Growth %: -39.0%
Financial Fact:
Other (expense) income: 229K
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -39.0%
Financial Fact:
Other (expense) income: 229K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q2 EPS of ($0.25), $0.06 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $20.81 million.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Barclays says AI trade is maturing, favors greater diversification
- Lumentum shares rise on analyst upgrades, AI demand outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
